Abstract: An aircraft and an aircraft wing assembly for an aircraft. The wing assembly includes a wing body assembly including a wing body; and at least one protruding portion connected to the wing body. The protruding portion extends aftwardly from an aft side of the wing body assembly, a leading edge of the wing body assembly defining a leading edge line, a trailing edge of the wing body assembly defining a trailing edge line extending between the inboard end and the outboard end, the trailing edge including a trailing edge of the protruding portion, the trailing edge line being a smooth line, a chord distance being defined longitudinally from the leading edge line to the trailing edge line, the chord distance at a center of the protruding portion being greater than the chord distance inboard of protruding portion and outboard of the protruding portion.

Abstract: A winglet system for a wing of an aircraft is provided. The winglet system comprises an attachment end for attachment to a main wing of the aircraft, an upper winglet and a lower winglet. The upper and lower winglets are staggered and also overlap one another along the chord of the attachment end. A spanwise profile of the lower winglet has a midpoint where a slope of the spanwise profile at a point outboard of the midpoint is inclined more upwardly than a slope of the spanwise profile at the midpoint. The configuration of the winglet system may provide benefits such as a reduced bending moment and reduced negative interference between the winglets while also managing ground clearance.

Abstract: An aircraft and an aircraft wing assembly for an aircraft. The wing assembly includes a wing body assembly including a wing body; and at least one protruding portion connected to the wing body. The protruding portion extends aftwardly from an aft side of the wing body assembly, a leading edge of the wing body assembly defining a leading edge line, a trailing edge of the wing body assembly defining a trailing edge line extending between the inboard end and the outboard end, the trailing edge including a trailing edge of the protruding portion, the trailing edge line being a smooth line, a chord distance being defined longitudinally from the leading edge line to the trailing edge line, the chord distance at a center of the protruding portion being greater than the chord distance inboard of protruding portion and outboard of the protruding portion.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.

Abstract: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.